News About: R&D
Dong-A to receive $17 million in royalties from Trius Therapeutics
Trius Therapeutics, U.S. based pharmaceutical company, is to pay some $17 million in royalties for the development of Dong-A’s new second generation oral and IV oxazolidinone antibiotic (DA-7218), as Trius Therapeutic...
Daewon to launch new anti-inflammatory drug in OctoberDaewon Pharm plans to launch its new nonsteroidal anti-inflammatory drug, Peluvi tablets (felubiprofen) from next month as the drug is eligible for the national health insurance...
|
Korean AIDS patients and activists calling for compulsory license of Fuzeon
Korea should move a step closer to breaking the drug patent of Fuzeon by asking the Swiss drug giant Roche for the right to copy the product so the country can slash medication costs, according to Korean AIDS patients...
U.S. Scientists demonstrate efficacy of VM202
A team of the U.S. scientists have discovered that VM202, a newly constructed plasmid human hepatocyte growth factor, improved myocardial perfusion, viability, and LV function in pigs, opening new possibilities for tr...
Health ministry to nurture 13,000 youths
The Ministry of Health, Welfare and Family Affairs plans to train 13,000 young employees for new drug development and other medical industries over the next five years.
Under the envisioned plan to produce skilled ...
Ivabradine reduces myocardial infarction and revascularization in coronary patients with HR>70 bpmThe results of the BEAUTIFUL (Morbidity-Mortality Evaluation of the Inhibitor Ivabradine in Patients with Coronary Disease and Left Ventricular Dysfunction) study, presented at ...
|
Merck Korea to launch easypod, new electronic growth hormone injection deviceMerck Korea will launch its unique growth hormone injection device, easypod, from next month for the once-daily administration of Saizen (somatropin), the company's recombinant ...
|
Daewoong, Oscotec to develop new natural pharmaceutical product for arthritisDaewoong Pharm said on September 10 that it has signed a memorandum of understanding with Oscotec Inc., a local bone specialized bioengineering company to develop BT-201, a natu...
|
Health insurance to cover new chemically modified drug price up to 90% of original drug
When a chemically modified drug with a new dosage and administration gets listed for insurance coverage, the price will be calculated by 90 percent of the corresponding original drug, the Ministry of Health, Welfare a...
GSK undecided on price of Cervarix vaccine
GlaxoSmithKline has yet to decide on price, launching date and partnership of Cervarix, cervical cancer vaccine, a GSK official said on September 1.
The company is scheduled for Cervarix’s launching symposium soon ...
